Scholarlink

Background <p>Periprosthetic joint infection (PJI) remains one of the most serious. Advances in metal-artefact-reduction sequences (MARS) now allow for improved diagnostic quality imaging in the periprosthetic region. Early studies suggest the diagnostic efficacy of MARS, including subfeatures, yet no formal synthesis of available data exists.</p> Methods <p>A systematic review and meta-analysis were conducted following PRISMA-DTA and PRISMA 2020 guidelines. Eligible studies include diagnostic accuracy studies reporting MARS-MRI compared with established reference standards, such as Musculoskeletal Infection Society (MSIS) or International Consensus Meeting (ICM) criteria, or intraoperative microbiology and histology. Adults (≥18 years) with hip, knee, or shoulder arthroplasty undergoing MRI for suspected infection or aseptic loosening were included. Comprehensive searches were conducted in PubMed, Embase, Scopus, and Web of Science, from 2005 onwards, without language restriction.</p> Results <p>A total of 11 studies were included in this meta-analysis evaluating MARS-MRI for diagnosing periprosthetic joint infection (PJI). Pooled performance demonstrated high diagnostic accuracy with sensitivity 0.88 (95% CI 0.72–0.95), specificity 0.95 (95% CI 0.80–0.99), and AUC 0.94. Subgroup analysis showed soft tissue changes had the best diagnostic performance (sensitivity 0.82, specificity 0.91), followed by synovitis and effusion, whilst bone changes were less accurate. Overall, MARS-MRI demonstrates excellent utility in diagnosing PJI.</p> Conclusion <p>MARS-MRI demonstrates high diagnostic accuracy for periprosthetic joint infection (sensitivity 0.88, specificity 0.95, AUC 0.94), particularly with soft tissue changes. It aids antimicrobial stewardship by reducing unnecessary interventions. Further large, multi-centre prospective studies are needed to strengthen evidence and validate clinical utility.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metal-artefact-reduction MRI for diagnosing periprosthetic joint infection: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年3月6日

查看全文
  • Ben Thompson,
  • Jonathan Gibson,
  • Tanwen Bird,
  • Jamie Arbuthnot,
  • Rajesh Botchu

摘要

Background

Periprosthetic joint infection (PJI) remains one of the most serious. Advances in metal-artefact-reduction sequences (MARS) now allow for improved diagnostic quality imaging in the periprosthetic region. Early studies suggest the diagnostic efficacy of MARS, including subfeatures, yet no formal synthesis of available data exists.

Methods

A systematic review and meta-analysis were conducted following PRISMA-DTA and PRISMA 2020 guidelines. Eligible studies include diagnostic accuracy studies reporting MARS-MRI compared with established reference standards, such as Musculoskeletal Infection Society (MSIS) or International Consensus Meeting (ICM) criteria, or intraoperative microbiology and histology. Adults (≥18 years) with hip, knee, or shoulder arthroplasty undergoing MRI for suspected infection or aseptic loosening were included. Comprehensive searches were conducted in PubMed, Embase, Scopus, and Web of Science, from 2005 onwards, without language restriction.

Results

A total of 11 studies were included in this meta-analysis evaluating MARS-MRI for diagnosing periprosthetic joint infection (PJI). Pooled performance demonstrated high diagnostic accuracy with sensitivity 0.88 (95% CI 0.72–0.95), specificity 0.95 (95% CI 0.80–0.99), and AUC 0.94. Subgroup analysis showed soft tissue changes had the best diagnostic performance (sensitivity 0.82, specificity 0.91), followed by synovitis and effusion, whilst bone changes were less accurate. Overall, MARS-MRI demonstrates excellent utility in diagnosing PJI.

Conclusion

MARS-MRI demonstrates high diagnostic accuracy for periprosthetic joint infection (sensitivity 0.88, specificity 0.95, AUC 0.94), particularly with soft tissue changes. It aids antimicrobial stewardship by reducing unnecessary interventions. Further large, multi-centre prospective studies are needed to strengthen evidence and validate clinical utility.